368426-78-2

Basic information

• Product Name: 3-Amino-1,2-benzisoxazole-6-methanamine
• Synonyms: 1,2-Benzisoxazole-6-methanamine,3-amino-(9CI);1,2-Benzisoxazole-6-methanamine, 3-amino;3-Amino-1,2-benzisoxazole-6-methanamine;6-(aminomethyl)benzo[d]isoxazol-3-amine
• CAS NO: 368426-78-2
• Molecular Formula: C₈H₉N₃O
• Molecular Weight: 163.18
• Product Categories: OXAZOLE
• Mol File: 368426-78-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 388.272 °C at 760 mmHg
• Flash Point: 188.62 °C
• Appearance: /
• Density: 1.339 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.702
• CAS DataBase Reference: 3-Amino-1,2-benzisoxazole-6-methanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Amino-1,2-benzisoxazole-6-methanamine(368426-78-2)
• EPA Substance Registry System: 3-Amino-1,2-benzisoxazole-6-methanamine(368426-78-2)

Safety Data

• Hazardous Substances Data: 368426-78-2(Hazardous Substances Data)

Usage

Uses

3-Amino-1,2-benzisoxazole-6-methanamine is used in the preparation of MASP-2 inhibitors.

InChI:InChI=1/C8H9N3O/c9-4-5-1-2-6-7(3-5)12-11-8(6)10/h1-3H,4,9H2,(H2,10,11)

Upstream product

• 229623-53-4 6-cyano-3-amino-1,2-benzisoxazole 
• 368426-77-1 tert-butyl ((3-aminobenzo[d]isoxazol-6-yl)methyl)carbamate 
• 229623-55-6 4-(tert-butoxycarbonylaminomethyl)-2-fluorobenzonitrile 
• 105942-08-3 4-bromo-6-fluorobenzonitrile 
• 1897-53-6 2-fluoroterephthalonitrile 

Downstream Products

• 308834-73-3 C₂₄H₂₄ClN₇O₃ 

Relevant articles and documents

FACTOR XIIa INHIBITORS

This invention relates to compounds of formula (I). The compounds of formula (I) are modulators of Factor XII, specifically Factor XIIa. The compounds are inhibitors of Factor XIIa and may be useful as anticoagulants. The compounds of formula (I) may be used in methods of treatment (or prevention) of blood disorders related to bleeding or coagulation.

Design, synthesis, and biological evaluation of pyrazinones containing novel P1 needles as inhibitors of TF/VIIa

Herein is described the design, synthesis, and enzymatic activity of a series of substituted pyrazinones as inhibitors of the TF/VIIa complex. These inhibitors were designed to explore replacement and variation of the P1 amidine described previously [J. Med. Chem. 2003, 46, 4050]. The P1 needle replacements were selected based upon their reduced basicity compared to the parent phenyl amidine (pKa ～ 12). A contributing factor towards the oral bioavailability of a compound is the ionization state of the compound in the intestinal tract. The desired outcome of the study was to identify an orally bioavailable TF-VIIa inhibitor.

THROMBIN INHIBITORS

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein b is N Y 1 or O; c is CY 2 or N; d is CY 2; e is CY 1 or N; f is CY 1 or N; g is CY 1 or N; Y 1 is hydrogen, C 1-4 alkyl, or halogen; Y 2 is hydrogen, C 1-4 alkyl, C 3-7 cycloalkyl, halogen, NH 2, OH or C 1-4 alkoxy;A is and W, X, Z, R 3, R 4 and R 5 are defined in the specification.